PROGRAM CHAIR
Komal Jhaveri, MD, FACP, FASCO
Associate Professor
Department of Medicine
Breast Medical Oncologist
Early Drug Development Specialist
Memorial Sloan Kettering Cancer Center
Associate Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York
FACULTY
Ruta Rao, MD
Professor of Medicine
Rush University Medical Center
Chicago, Illinois
PROGRAM OVERVIEW
This enduring activity is designed to advance your expertise in utilizing PI3K-pathway inhibitors for patients with hormone-receptor-positive, HER2-negative metastatic breast cancer. Combining didactic presentation with engaging case-based discussions alongside peers and expert faculty, the program explores personalized, multidisciplinary treatment strategies, effective adverse event management with an emphasis on blood sugar optimization, and key clinical challenges.
TARGET AUDIENCE
This innovative educational initiative is designed to meet the educational needs of community oncologists, oncology care team members (eg, pharmacists, advanced practice providers, nurses), and endocrinologists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select the most appropriate PI3K pathway inhibitor for patients with HR+/HER2- mBC based on the tumor mutational profile
- Summarize the mechanisms underlying hyperglycemia associated with PI3K pathway inhibitors, the characteristics of these AEs, and the impact on patients with HR+/HER2- metastatic breast cancer
- Develop strategies to monitor and manage hyperglycemia and other adverse events associated with PI3K pathway inhibitors effectively and promptly within an MDT
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Komal Jhaveri, MD | Discloses that she receives consulting fees from: Novartis, Pfizer, Genentech, Eisai, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline Therapeutics, Gilead Sciences, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck, Zymeworks, Halda Therapeutics, Arvinas, and RayzeBio. She receives research funds from: Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead Sciences, PUMA Biotechnology, Merck, Scorpion Therapeutics, RayzeBio, Eisai, and Blueprint Medicines |
| Ruta Rao, MD | Discloses that she receives consulting fees from: AstraZeneca, Daiichi Sankyo, Pfizer, Lilly, TerSera Therapeutics, and Genentech |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shannon Mutch, MS, RN, OCN, has nothing to disclose.
- Andi Koral, MS, CMP-HC, Program Manager for Med Learning Group, has nothing to disclose.
- Liz Griffin, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 18, 2025
EXPIRATION DATE: December 18, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
